A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers
A Randomized, Placebo-Controlled, Four-Period Crossover, Study to Evaluate the Effect of Volanesorsen on the QTc Interval Using a Therapeutic and Supra-Therapeutic Dose Compared With Placebo in Healthy Volunteers: a Thorough QT Study
Sponsor: Akcea Therapeutics
Listed as NCT02910635, this PHASE1 trial focuses on Abnormalities, Cardiovascular and remains completed. Sponsored by Akcea Therapeutics, it has been updated 8 times since 2016, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Feb 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Feb 2022 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Apr 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Akcea Therapeutics
- Ionis Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .